Keep Leukemia Away®

The four main leukemias

Who is at risk

• Most people have no identifiable risk factor. Leukemia is not caused by anything you did.
• Age — most leukemias become more common with age, though ALL peaks in early childhood.
• Previous chemotherapy or radiation for another cancer can cause therapy-related leukemia years later.
• Benzene and some other industrial chemical exposures; heavy cigarette smoking is linked to AML.
• Certain genetic conditions — Down syndrome, Fanconi anaemia, Li-Fraumeni and others.
• Some blood disorders — myelodysplastic syndrome and myeloproliferative neoplasms can evolve into AML.
• Family history in CLL specifically, where familial clustering is recognised.

Finding it early

There is no screening test for leukemia, and the acute forms can appear over days to weeks — there is often no early window to catch.

Symptoms come from the marrow being crowded out, so they are the symptoms of missing blood cells: fatigue and breathlessness from anaemia, infections that keep coming back or will not clear from low white cells, and easy bruising, tiny red skin spots, nosebleeds or bleeding gums from low platelets. Add bone or joint pain, night sweats, unexplained fever, weight loss, and swollen nodes, spleen or liver.

Chronic leukemias are frequently found by accident — an abnormal white cell count on a blood test done for something else entirely. Many people with CLL feel completely well at diagnosis.

A full blood count is a cheap, fast, widely available test. Unexplained bruising, repeated infection or persistent fatigue in an adult or a child is a reasonable reason to ask for one.

How it’s diagnosed

It usually starts with a full blood count and a blood film. A bone marrow aspirate and biopsy then confirms the diagnosis and type.

The specialised tests are what actually determine treatment: flow cytometry to identify the cell type; cytogenetics and FISH for chromosome changes; and molecular testing for mutations such as FLT3, NPM1 and IDH in AML, BCR-ABL in CML, and IGHV and TP53 status in CLL.

A lumbar puncture is done in ALL and some AML to check whether the fluid around the brain and spinal cord is involved.

Ask for the exact subtype and the genetic findings. In leukemia these are not academic detail — they decide whether you receive a tablet, intensive chemotherapy, or a transplant.

Staging explained simply

There is no standard staging system for leukemia in the way there is for solid tumours. Because leukemia begins in blood and marrow, it is already everywhere at diagnosis — so "has it spread?" is not the useful question. SEER itself notes that leukemia is described instead as untreated, in remission, or recurrent.

What replaces staging is risk classification, and each leukemia has its own:

• AML — favourable, intermediate or adverse risk, based on cytogenetics and mutations (ELN classification).
• CLL — the Rai and Binet systems, based on blood counts, nodes, spleen and liver; refined by TP53 and IGHV status.
• CML — chronic, accelerated or blast phase, plus response milestones measured by BCR-ABL levels.
• ALL — risk group by age, white cell count, genetics and response to early treatment.

So if you are searching for "stage 4 leukemia," you will not find it — and that is not because information is being withheld.

Grading and biology

Leukemia is not graded 1–3. The equivalent distinction is acute versus chronic, and it is about maturity, not severity of character.

Acute leukemias are made of immature blast cells that cannot function and multiply rapidly — they need treatment urgently, often within days. Chronic leukemias involve more mature cells and progress over years; some are watched rather than treated for a long time.

Genetics carry the weight that grade carries elsewhere. A FLT3 or NPM1 mutation in AML, TP53 in CLL, the Philadelphia chromosome in CML or ALL — these determine treatment far more than anything visible under a microscope. Measurable residual disease (MRD) after treatment is now one of the strongest predictors of outcome.

How it’s treated

AML — intensive chemotherapy to induce remission, then consolidation, with stem cell transplant for higher-risk disease. Targeted drugs are added for specific mutations. Gentler regimens combining venetoclax with a hypomethylating agent have made effective treatment possible for older and less fit patients who once had few options.

ALL — long, multi-phase chemotherapy over roughly two to three years, including treatment directed at the brain and spinal fluid. Children do remarkably well. Immunotherapies and CAR T-cell therapy have improved relapsed disease substantially.

CLL — many people need no treatment for years, and watchful waiting is standard for early asymptomatic disease. When treatment is needed, targeted tablets (BTK inhibitors, venetoclax) have largely replaced chemotherapy.

CML — a daily targeted tablet (a tyrosine kinase inhibitor) controls the disease in most people, with normal or near-normal life expectancy. Some who achieve deep sustained responses can even stop the drug under careful monitoring. This is one of the most complete transformations in the history of cancer medicine.

Radiation has a defined, narrower role in leukemia than in most cancers: total body irradiation as part of conditioning before a stem cell transplant, treatment of a chloroma (a solid collection of leukemic cells), radiation to the brain or testes in selected ALL cases, splenic radiation for painful enlargement, and symptom relief for bone pain.

Where CureRays fits: we will be straight with you — leukemia is led by haematologists, and radiation is a supporting player. Where it helps, it helps a great deal; where it does not, we will say so.

What the guidelines say

In broad strokes: identify the exact subtype with flow cytometry, cytogenetics and molecular testing before treating; treat acute leukemias urgently with subtype-specific regimens; use risk classification and measurable residual disease to decide who needs a transplant; observe early asymptomatic CLL; treat CML with a tyrosine kinase inhibitor and monitor BCR-ABL against response milestones; and use radiation for transplant conditioning, chloroma, sanctuary sites and symptom control.

Your team will follow national guidelines such as those from the National Comprehensive Cancer Network (NCCN). The above is a plain-language overview of the general approach, not the guideline itself. NCCN publishes free NCCN Guidelines for Patients® for each leukemia type.

Outcomes and odds of cure

We are not going to give you a single leukemia survival figure, because it would be misleading. Childhood ALL and AML in an older adult are different diseases with different outlooks, and averaging them serves nobody.

Broadly, and with that caveat: childhood ALL is one of the great successes of modern oncology, with cure rates now above 90% in many series. CML treated with targeted tablets is compatible with a near-normal lifespan for most. CLL is very treatable and often needs no treatment for years. AML remains the most difficult, with outcomes depending heavily on age and genetic risk group.

For figures matched to your own diagnosis, use the SEER page for your specific subtype — AML, ALL, CLL, CML — and ask your haematologist for numbers based on your risk group and response to the first phase of treatment, which predict far better than any population average.

A note on our sourcing: SEER's combined "leukemia" overview page was an outdated snapshot when we checked it, so we have not quoted an aggregate figure from it rather than present stale data as current.

Population statistics describe large groups, not individuals, and lag current treatment by years. They cannot predict what will happen to you.

Side effects and how we watch for them

The central risk during intensive treatment is infection. When the white count is low, a fever is a medical emergency — antibiotics are needed within the hour. Do not wait until morning, and do not take paracetamol to see if it settles. Know your unit's 24-hour number and use it.

Also expected: anaemia and low platelets needing transfusion, mouth sores, nausea, hair loss, and fatigue that outlasts treatment by months.

Tumour lysis syndrome can occur when a large number of leukemia cells break down quickly at the start of treatment; it is anticipated and prevented with fluids and medication.

Targeted tablets have their own profiles — BTK inhibitors can cause bruising, atrial fibrillation and blood pressure changes; TKIs in CML can cause fluid retention, rash and cramps. Most are manageable with dose adjustment rather than stopping.

Total body irradiation before transplant carries long-term risks including infertility, cataracts, thyroid and lung effects, and second cancers — which is why fertility preservation should be discussed before conditioning.

How it is assessed: graded at each visit on a standard scale, with continuous blood count monitoring and, for CML, scheduled BCR-ABL measurement against response milestones.

Follow-up, remission and survivorship

Remission in leukemia means normal blood counts and under 5% blasts in the marrow. MRD-negative remission — no leukemia detectable by sensitive molecular testing — is a deeper and more meaningful result, and increasingly guides whether further treatment is needed.

Follow-up is blood counts and clinical review, frequent at first and stretching out over years; marrow tests when results change. In CML, BCR-ABL is measured on a set schedule and the numbers matter — ask what yours is and what it should be.

Survivorship after leukemia is a long project, particularly for people treated young: heart function after anthracyclines, fertility, bone density, thyroid, cataracts and second cancers after transplant or total body irradiation, plus vaccination — childhood immunity is lost after transplant and the schedule must be repeated. Ask for a written survivorship plan naming who monitors what.

Questions people actually ask

Informational only, not medical advice — confirm with your care team.

Go deeper on leukemia

Read the full plain-language guide, or ask us about radiation's supporting role in your treatment.

Full leukemia guide